UroGen Pharma Ltd.'s SEC filings document operating results, product revenue disclosures, financing agreements and governance matters for a biotechnology company focused on urothelial and specialty cancers. Recent 8-K reports furnish quarterly and annual financial results tied to JELMYTO and ZUSDURI, commercial launch updates, research and development expenses, reimbursement matters and pipeline disclosures involving UGN-103 and UGN-501.
Other filings describe material definitive agreements, including term-loan refinancing and credit arrangements with BioPharma Credit entities, as well as capital-structure information for ordinary shares listed on Nasdaq. Definitive proxy statements cover board matters, executive compensation, equity awards, pay-versus-performance tables and shareholder voting matters.
UroGen Pharma Ltd. (URGN) Chief Financial Officer Chris Degnan settled 4,483 restricted stock units into 4,483 ordinary shares on October 8, 2026. He sold 2,202 ordinary shares at $36.69 per share to satisfy withholding tax obligations upon the RSU settlement. The derivative transaction reports 4,484 restricted stock units following settlement. No Rule 10b5-1 plan is reported.
UroGen Pharma Ltd. officer Christopher Degnan reported a proposed sale of 2,202 ordinary shares, with an aggregate market value of $89,621.40 and an approximate sale date of October 8, 2026. The notice lists 8,966 ordinary shares issued upon vesting of RSUs for no consideration. Meirav Shemesh, Authorized Signatory, Oppenheimer Israel (pursuant to delegation), signed the notice.
UroGen Pharma Ltd. (URGN) reported insider equity transactions by Chief Medical Officer Mark Schoenberg. On September 7, 2026, 1,667 Restricted Stock Units (RSUs), each representing a contingent right to receive one ordinary share, were settled into 1,667 ordinary shares at a price of $0 per share. These RSUs come from a grant made on September 7, 2023 representing 5,000 ordinary shares that vest in three equal annual installments from September 7, 2024.
On September 8, 2026, Schoenberg sold 871 ordinary shares at $42.92 per share in a direct open-market or private transaction. A footnote states that these shares were sold to satisfy withholding tax obligations upon the RSU settlement. No Rule 10b5-1 trading plan is reported for these transactions.
UroGen Pharma Ltd. (URGN) reported that General Counsel Jason Drew Smith settled a tranche of equity awards and related tax obligations. On September 7, 2026, he exercised 3,334 Restricted Stock Units, receiving an equal number of ordinary shares at no cash exercise price. On September 8, 2026, 1,519 ordinary shares were sold at $42.54 per share to satisfy withholding tax obligations tied to this RSU settlement; no Rule 10b5-1 trading plan is reported.
The RSUs exercised are part of a grant awarded on September 7, 2023 covering 10,000 ordinary shares, scheduled to vest in three equal annual installments beginning September 7, 2024.
UroGen Pharma Ltd. (URGN) has a Form 144 notice indicating that officer Mark Schoenberg may sell up to 5,000 ordinary shares of UroGen Pharma Ltd. These shares were issued on September 8, 2026 upon vesting of restricted stock units and involve no cash consideration to him.
The planned sale is through Oppenheimer & Co. Inc. The notice also reports that Schoenberg sold 5,222 ordinary shares on June 8, 2026 for $142,560.60, with the remark that those shares were sold to cover tax withholding obligations upon vesting of equity awards.
UroGen Pharma Ltd. (URGN) filed a notice that officer Jason Smith may sell ordinary shares under Rule 144. The notice covers 10,000 ordinary shares, which were issued on September 8, 2026 upon vesting of RSUs, with no cash consideration. A portion of the shares is indicated as being sold to cover tax withholding obligations related to these equity awards, and Oppenheimer & Co. Inc. is listed as the broker.
UroGen Pharma Ltd. (URGN) director James A. Robinson Jr. reported the exercise and settlement of equity awards. On 2026-08-26, he exercised 2,000 Restricted Stock Units, each representing a contingent right to receive one ordinary share, which converted into 2,000 ordinary shares of UroGen.
The derivative RSU position of 2,000 units was fully settled, leaving no RSUs from this award outstanding, and Mr. Robinson’s directly held ordinary shares increased to 8,000 shares following the transaction.
UroGen Pharma Ltd. (URGN) reported that Chief Medical Officer Mark Schoenberg sold 60,677 ordinary shares on 2026-08-20 in an open market or private transaction. The weighted average sale price was $47.05 per share, with prices ranging from $46.30 to $49.70. Following the sale, Schoenberg directly holds 59,086 ordinary shares.
UroGen Pharma Ltd. (symbol URGN) received a Form 144 notice indicating that officer Mark Schoenberg plans sales of common shares under Rule 144, with RBC Capital Markets LLC as the broker. The common stock is listed on Nasdaq. The shares to be sold were acquired through a stock option exercise from the issuer on January 27, 2023. Over the prior three months, Schoenberg reported two Rule 144 sales of UroGen common stock totaling 20,000 shares, for gross proceeds of $400,008.00 on July 9, 2026 and $350,143.00 on June 22, 2026.
UroGen Pharma Ltd. (URGN) reported that its wholly owned subsidiary, UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. on August 18, 2026. UroGen obtained an exclusive option to secure an exclusive, worldwide license to IntraGel’s TumoCure product formulated with IntraGel’s proprietary SRGel platform for treating advanced head and neck cancer, options for additional SRGel-based products designated by UroGen, and a non-exclusive license to research and evaluate the SRGel platform.
In a related transaction, UroGen Pharma Ltd. agreed, under a Securities Purchase Agreement with IntraGel, to invest up to $7,000,000 in IntraGel’s equity securities, aligning its financial commitment with the collaboration’s development and evaluation activities.